AM-168

N/A

Report date: 2023/10/16 13:59:17

Base Information

Drug NameAM-168
Drug Alias NameAM-168
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-Receptor tyrosine-protein kinase erbB-3
TargetsReceptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAcadeMab Biomedical Inc
China Registration ClassN/A

Develop Information

Active CompaniesAcadeMab Biomedical Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A